The safety profile of cagrilintide-semaglutide was broadly consistent with that reported for other incretin-based therapies, although gastrointestinal adverse events and treatment discontinuations occurred more frequently than with either semaglutide or cagrilintide alone, highlighting the importance of careful patient selection and long-term adherence
Experimental studies in animal models and in vitro systems suggest that DSIP can influence the release of hormones such as growth hormone, luteinizing hormone, and adrenocorticotropic hormone through both hypothalamic and pituitary-level mechanisms [8]
All of this sits on top of his long-running testosterone replacement therapy
announced that roughly 14 of those 19 peptides, including BPC-157 and TB-500, were expected to move back toward legal compounding status
Should I talk to my own provider first
The Bottom Line Although AOD-9604, MOTS-c, Tesamorelin, Semaglutide, and Tirzepatide are often discussed together, they serve very different purposes